Neonatal Jaundice (Hyperbilirubinemia): Case Discussion & Key Learning Points
Model Case Presentation
Patient Demographics
Name: Baby of Mrs. Priya, Age: Day 3 of life, Gender: Male, Gestational Age: 38 weeks (term), Informant: Mother (Reliable)
Chief Complaints
- Yellow discoloration of skin and eyes — noticed on day 2 of life
- Progressively increasing jaundice — now extending to chest and abdomen
History Summary
Baby born via LSCS to a 26-year-old primigravida (Blood group O positive). Birth weight 3.1 kg, cried immediately. Jaundice was first noticed at 30 hours of life on the face. Over the next 24 hours it has spread to the trunk. Baby is breastfeeding with moderate latch, feeding 8-10 times per day. Not excessively lethargic, no seizures, no high-pitched cry, no fever. Urine is yellow; stools are yellow-green. Apgar was 8/9. No maternal illness during pregnancy. No prior sibling with jaundice or blood transfusion history. Mother's blood group O+, baby's blood group A+.
Risk factors identified: ABO incompatibility (mother O+, baby A+), borderline gestational age (38 weeks), primipara with possible suboptimal breastfeeding leading to inadequate intake.
Examination Summary
| Parameter | Finding | Significance |
|---|---|---|
| Weight | 2.95 kg (5.1% loss) | Borderline weight loss — may worsen jaundice |
| Jaundice (Kramer's Zone) | Zone 3 (up to umbilicus) | Estimated bilirubin ~8–16 mg/dL |
| Temp | 37.0°C | Normal — against sepsis |
| HR | 140/min | Normal |
| Sensorium | Alert, active | No acute bilirubin encephalopathy |
| Cry | Normal pitch | No kernicterus signs |
| Tone | Normal | No hypotonia |
| Scleral icterus | Present | Confirms clinical jaundice |
| Pallor | Mild | Suggests hemolysis |
| Hepatosplenomegaly | Mild (liver 2 cm BCM) | Consistent with hemolysis |
Abdomen: Liver palpable 2 cm below right costal margin. Spleen tip palpable. Abdomen soft, non-tender.
CNS: Alert, Moro's reflex present and symmetric. Fontanelle — flat. No opisthotonus, no setting sun sign.
Stools/Urine: Stool — yellow-green (normal), Urine — yellow (not pale stools or dark urine, making cholestasis unlikely).
✅ Complete Diagnosis
Neonatal Jaundice — Pathological (onset <24 hours of age) — ABO Incompatibility (Mother O+, Baby A+) with Hemolysis — Day 3 of life — Kramer's Zone 3 — No features of Acute Bilirubin Encephalopathy — Borderline weight loss — likely compounded by suboptimal breastfeeding.
📝 History — Exam Q&A
Neonatal jaundice is yellow discoloration of the skin and sclerae in a neonate due to elevated serum bilirubin. It becomes clinically visible when Total Serum Bilirubin (TSB) exceeds 5–7 mg/dL. It affects ~60% of term and ~80% of preterm neonates in the first week of life.
| Feature | Physiological | Pathological |
|---|---|---|
| Onset | After 24 hours | <24 hours of life |
| Rate of rise | <5 mg/dL/day | >5 mg/dL/day |
| Peak TSB (term) | <12–13 mg/dL (by day 3–4) | >17 mg/dL |
| Peak TSB (preterm) | <15 mg/dL | >15 mg/dL |
| Duration | <14 days (term), <21 days (preterm) | Prolonged (>14/21 days) |
| Direct bilirubin | <2 mg/dL or <20% of TSB | >2 mg/dL or >20% of TSB |
| Clinical well-being | Well baby | May be unwell |
💡 Key Mnemonic
Pathological jaundice: "Before 24 — Always Bad" — Jaundice appearing before 24 hours is ALWAYS pathological and requires immediate investigation.
Jaundice within 24 hours is always pathological. Causes are predominantly hemolytic:
- Rh incompatibility (Erythroblastosis fetalis) — most severe hemolytic cause
- ABO incompatibility — most common cause of early hemolytic jaundice
- G6PD deficiency — X-linked, hemolysis triggered by oxidant stress
- Hereditary Spherocytosis
- Congenital infections (TORCH) — CMV, Rubella, Toxoplasma
- Sepsis (early-onset)
- Physiological jaundice (most common)
- Breastfeeding jaundice (inadequate intake)
- ABO incompatibility
- G6PD deficiency
- Polycythemia
- Cephalohematoma / bruising / internal hemorrhage
- Sepsis
Predominantly indirect (unconjugated) hyperbilirubinemia:
- Breast milk jaundice — most common cause in a well, thriving baby
- Hypothyroidism — must always be excluded (neonatal screening)
- G6PD deficiency, hereditary spherocytosis
- Crigler-Najjar syndrome (Type I or II — UGT1A1 deficiency)
- Gilbert syndrome
Direct (conjugated) hyperbilirubinemia — Neonatal Cholestasis:
- Biliary atresia — surgical emergency; pale stools + dark urine
- Neonatal hepatitis syndrome
- Choledochal cyst
- Alagille syndrome
- Metabolic: Galactosemia, Tyrosinemia, α-1 antitrypsin deficiency
- Sepsis (especially UTI — E. coli)
🚨 Never Miss
Pale (acholic) stools + prolonged jaundice = Biliary atresia until proven otherwise. Refer before 60 days for Kasai procedure (best outcomes).
| Feature | Breastfeeding Jaundice | Breast Milk Jaundice |
|---|---|---|
| Onset | Day 2–4 | After day 4–5, peaks at 2 weeks |
| Mechanism | Inadequate milk intake → dehydration → increased enterohepatic circulation | Inhibitors in breast milk (β-glucuronidase, free fatty acids) → increased enterohepatic circulation |
| Baby's weight | Losing weight / inadequate gain | Adequate weight gain, thriving |
| Feeding frequency | Suboptimal | Adequate — feeding well |
| Management | Improve breastfeeding, increase feeding frequency | Continue breastfeeding; temporary interruption (24–48h) used only if bilirubin dangerously high |
| Duration | Resolves with adequate feeding | Persists 6–12 weeks, gradually resolves |
Multiple factors combine to produce physiological jaundice in neonates:
- Increased bilirubin production: Fetal Hb (HbF) has a shorter RBC lifespan (70–90 days vs 120 days) → more bilirubin load. Neonates produce ~2x more bilirubin per kg than adults.
- Reduced hepatic uptake: Deficiency of ligandin (Y protein) in the first few days
- Reduced conjugation: Immature UGT1A1 enzyme activity (50% of adult activity in term; even lower in preterm)
- Increased enterohepatic circulation: Sterile gut + high β-glucuronidase activity → deconjugation and reabsorption of bilirubin
Major risk factors (AAP 2022):
- Predischarge TSB/TcB in high-risk zone (≥95th percentile on Bhutani nomogram)
- Gestational age <38 weeks
- Exclusive breastfeeding with inadequate intake / excessive weight loss
- Jaundice in first 24 hours
- Isoimmune hemolytic disease (ABO, Rh) / positive DCT
- G6PD deficiency
- Previous sibling requiring phototherapy
- Cephalohematoma or significant bruising
- East Asian race (↑ G6PD prevalence)
| Feature | ABO Incompatibility | Rh Incompatibility |
|---|---|---|
| Blood groups | Mother O, Baby A or B | Mother Rh –ve, Baby Rh +ve |
| First pregnancy | Can occur (IgG anti-A/anti-B naturally present) | Rarely in 1st pregnancy (sensitization needed) |
| Severity | Usually mild–moderate | Can be severe → hydrops fetalis |
| DCT | Weakly positive or negative | Strongly positive |
| Anemia | Mild or absent | Severe, progressive |
| Spherocytes on smear | Present | Not typical |
| Hydrops fetalis | Very rare | Classic complication |
| Prevention | No specific prevention | Anti-D immunoglobulin (RhoGAM) |
About jaundice: Time of onset, progression, associated symptoms (lethargy, poor feeding, fever, seizures, dark urine, pale stools).
About feeding: Breastfed or formula, frequency, adequacy, weight trend.
Birth history: Gestational age, mode of delivery, Apgar, birth weight, birth injuries (cephalohematoma).
Maternal history: Blood group, Rh status, antenatal serology (DCT, Rh antibody titers), medications (sulfonamides → hemolysis in G6PD), infections during pregnancy.
Family history: Previous jaundiced siblings requiring treatment, G6PD deficiency, hereditary spherocytosis, splenectomy.
Ethnic/geographic origin: Mediterranean, African, Asian — higher risk of G6PD deficiency.
Rare autosomal recessive disorder due to complete or partial deficiency of UGT1A1 (bilirubin UDP-glucuronosyltransferase).
| Feature | Type I (Severe) | Type II (Arias syndrome) |
|---|---|---|
| UGT1A1 activity | Absent (0%) | Markedly reduced (1–10%) |
| TSB | 25–50 mg/dL (very high) | 6–25 mg/dL |
| Bile color | Colorless (no bilirubin excreted) | Pigmented |
| Phenobarbital response | None | Yes (reduces TSB by >25%) |
| Risk of kernicterus | Very high — without treatment | Low in most, possible in stress |
| Treatment | 12–16 h/day phototherapy lifelong → liver transplant (curative) | Phenobarbital; phototherapy if needed |
🩺 Examination — Exam Q&A
Bilirubin-induced jaundice spreads in a cephalocaudal (head-to-toe) direction. Kramer described 5 zones with corresponding estimated bilirubin levels:
| Zone | Area Involved | Estimated Bilirubin (mg/dL) |
|---|---|---|
| Zone 1 | Face and head | 4–8 |
| Zone 2 | Trunk above umbilicus | 5–12 |
| Zone 3 | Trunk below umbilicus to umbilicus | 8–16 |
| Zone 4 | Arms + legs below knee | 11–18 |
| Zone 5 | Palms and soles | >15 (can exceed 20) |
🚨 Important Limitation
Kramer's zones are a rough clinical guide only. They are unreliable in dark-skinned babies, under phototherapy, and in preterm neonates. Always confirm with serum/transcutaneous bilirubin before treatment decisions.
ABE refers to the acute neurological dysfunction caused by unconjugated bilirubin crossing the blood-brain barrier and binding to brain tissue (particularly basal ganglia, hippocampus, subthalamic nuclei, cranial nerve nuclei).
| Stage | Features | Reversibility |
|---|---|---|
| Early (Phase 1) | Lethargy, hypotonia, poor suck, high-pitched cry | Fully reversible |
| Intermediate (Phase 2) | Stupor, irritability, hypertonia (retrocollis, opisthotonus), fever, high-pitched cry | Partially reversible |
| Advanced (Phase 3) | Deep stupor/coma, pronounced retrocollis-opisthotonus, apnea, seizures, inability to feed | Irreversible — death or kernicterus |
Kernicterus is the permanent neurological sequel of severe neonatal hyperbilirubinemia due to bilirubin deposition in the basal ganglia (globus pallidus, subthalamic nucleus), hippocampus, and brainstem nuclei. The classic tetrad of chronic kernicterus is:
- Choreoathetosis — involuntary writhing movements (most common and characteristic)
- Upward gaze palsy (paralysis of upward gaze)
- High-frequency sensorineural hearing loss (auditory neuropathy spectrum disorder)
- Dental enamel dysplasia of deciduous teeth
Spastic CP, intellectual disability, and seizures may also occur.
- Jaundice appearing within 24 hours
- Pallor — anemia from hemolysis
- Hepatosplenomegaly — extramedullary hematopoiesis + RES hyperplasia
- Hydrops fetalis (severe Rh disease) — generalized edema, ascites, pleural effusions
- Rapid progression of jaundice (>5 mg/dL/day)
- Pale/acholic (clay-colored) stools — absence of bile in gut (biliary atresia, intrahepatic cholestasis)
- Dark urine (bilirubinuria — conjugated bilirubin is water soluble)
- Prolonged jaundice (>14 days term, >21 days preterm)
- Hepatomegaly with firm, hard edge (biliary atresia)
- Splenomegaly (portal hypertension in advanced disease)
- Failure to thrive
- Fat-soluble vitamin deficiency signs (vitamin K — bleeding, vitamin D — rickets, vitamin E — neurological symptoms)
🚨 Stool Color Chart
The Stool Color Card (Taiwan/Taiwan model; now recommended by AAP) should be given to all parents at discharge to detect acholic stools early in biliary atresia. Pale stools in a jaundiced baby → refer urgently.
BIND (Bilirubin-Induced Neurological Dysfunction) Score is a structured clinical tool to objectively assess the degree of acute bilirubin encephalopathy. It evaluates three domains:
| Domain | Score 1 | Score 2 | Score 3 |
|---|---|---|---|
| Mental status | Sleepy, poor feeding | Irritability, jitteriness | Stupor/coma, seizures |
| Muscle tone | Slightly decreased | Hypertonia | Opisthotonus |
| Cry | High-pitched | Shrill/inconsolable | Absent/inconsolable |
Total score: 1–3 = Subtle ABE | 4–6 = Moderate ABE | 7–9 = Severe ABE (kernicterus). A score ≥1 with high TSB warrants urgent exchange transfusion consideration.
Cephalohematoma is a subperiosteal blood collection that does not cross suture lines. It causes extravascular hemolysis — the trapped blood is broken down → large bilirubin load → significant exacerbation of jaundice. A baby with a large cephalohematoma should be monitored closely for hyperbilirubinemia, even if otherwise physiological.
- Immature blood-brain barrier — easier passage of unconjugated bilirubin into CNS
- Low serum albumin — less buffering capacity; more free (unbound) bilirubin available
- Factors that displace bilirubin from albumin and increase free bilirubin: acidosis, hypoxia, hypothermia, hypoglycemia, drugs (sulfonamides, ceftriaxone), free fatty acids (from Intralipid, fasting)
- Preterm brains are especially vulnerable (lower gestation = lower threshold for neurotoxicity)
🔬 Investigations — Exam Q&A
Total Serum Bilirubin (TSB) — fractionated into direct and indirect components.
- TSB is the gold standard for treatment decisions
- Fractionation determines if unconjugated (indirect) or conjugated (direct) jaundice
- Direct bilirubin >2 mg/dL or >20% of TSB = conjugated hyperbilirubinemia → investigate for cholestasis
💡 Important
In any jaundiced neonate <24 hours — draw TSB stat. Do NOT wait. It is always pathological.
The Bhutani (hour-specific) nomogram plots TSB against postnatal age in hours for term and near-term infants. It stratifies infants into risk zones:
- Low risk zone (<40th percentile) — unlikely to develop significant hyperbilirubinemia
- Low-intermediate zone (40th–75th percentile)
- High-intermediate zone (75th–95th percentile)
- High risk zone (≥95th percentile) — significant risk of requiring phototherapy
Use: Predischarge TSB or TcB plotted on the nomogram guides follow-up timing after discharge. Higher risk zone → earlier follow-up. It forms the basis of universal predischarge bilirubin screening (AAP 2004, reinforced 2022).
Approximate TSB (mg/dL) thresholds at postnatal hours for term neonates. For clinical use, always refer to validated published nomogram.
First-line (all pathological jaundice):
- TSB — total, direct, indirect
- Blood group of baby and mother (ABO + Rh)
- Direct Coombs Test (DCT/DAT) — detects antibody-coated RBCs → positive in isoimmune hemolysis
- Complete blood count (CBC) + peripheral smear — anemia, reticulocytosis, spherocytes, fragmented cells
- Reticulocyte count — elevated in hemolytic jaundice
Second-line (based on clinical suspicion):
- G6PD enzyme assay — if in endemic area, family history, or hemolysis without clear cause
- Serum albumin — to assess bilirubin-binding capacity
- Blood culture, CRP, sepsis screen — if sepsis suspected
- Thyroid function tests (TSH, T4) — for prolonged jaundice / neonatal hypothyroidism
- TORCH serology, LFT — if congenital infection / hepatitis suspected
- Urine for reducing substances — galactosemia (if cholestasis + hepatomegaly)
TcB is a non-invasive method using a handheld bilirubinometer (e.g., Dräger JM-103, BiliChek) that shines light through the skin and uses spectrophotometry to estimate bilirubin levels.
Advantages: Non-invasive, no blood draw, instantaneous, painless, useful for screening and repeat measurements, reduces unnecessary blood sampling.
Limitations:
- Overestimates TSB in dark-skinned infants
- Inaccurate during or after phototherapy (phototherapy bleaches skin → falsely low TcB readings)
- Not recommended when TSB is near treatment threshold — always confirm with serum bilirubin
- Readings vary by device, site (forehead vs sternum), and gestational age
The Direct Coombs Test (Direct Antiglobulin Test — DAT) detects maternal IgG antibodies already bound to the surface of neonatal RBCs.
- Positive DCT → Isoimmune hemolysis → ABO incompatibility, Rh disease, minor blood group incompatibility
- Negative DCT with hemolysis → Consider G6PD deficiency, hereditary spherocytosis, pyruvate kinase deficiency
Note: DCT in ABO incompatibility is often only weakly positive (anti-A/B antibodies have lower affinity), whereas in Rh disease it is strongly positive.
- Fractionated bilirubin — direct bilirubin >2 mg/dL confirms cholestasis
- LFT — ALT, AST, GGT, ALP (GGT markedly elevated in biliary atresia)
- Prothrombin time (PT) — vitamin K-dependent factor deficiency (fat-soluble)
- Abdominal USG — gall bladder (absent/small GB in BA), choledochal cyst, triangular cord sign (fibrotic remnant at porta hepatis in biliary atresia)
- HIDA scan (Hepatobiliary scintigraphy) — radionuclide excreted into gut = rules out BA; no excretion = suggests BA. Note: Give phenobarbital 5 mg/kg/day x 5 days before scan to improve sensitivity.
- Liver biopsy — bile duct proliferation in biliary atresia vs giant cell hepatitis in neonatal hepatitis
- Intraoperative cholangiogram — definitive diagnosis of biliary atresia
- Metabolic workup: urine reducing substances, plasma amino acids, TORCH, alpha-1 antitrypsin level and phenotype
Unconjugated bilirubin is transported in blood bound to albumin. Only the free (unbound) fraction crosses the blood-brain barrier and causes neurotoxicity.
- Low albumin (<3 g/dL) → more free bilirubin → increased neurotoxicity risk at any given TSB level
- AAP 2022 guidelines include albumin level in thresholds: if albumin <3 g/dL, use a lower phototherapy/ET threshold
- Bilirubin/Albumin (B/A) ratio can be used as a surrogate for free bilirubin; a high ratio increases risk for neurotoxicity
💊 Management — Exam Q&A
Phototherapy uses light energy to convert insoluble unconjugated bilirubin in the skin into water-soluble photoisomers that can be excreted in bile and urine without hepatic conjugation.
Three mechanisms:
- Configurational isomerization (fastest, reversible) — 4Z,15Z-bilirubin → 4Z,15E-bilirubin (lumirubin excreted in bile)
- Structural isomerization (lumirubin formation, irreversible) — most clinically important pathway; excreted in urine and bile
- Photooxidation (slowest) — bilirubin oxidized to colorless polar products excreted in urine
Optimal wavelength: 460–490 nm (blue-green spectrum). Special blue fluorescent lamps or LED phototherapy units are used.
Key factors affecting efficacy: Irradiance (≥30 μW/cm²/nm for intensive PT), surface area exposed, distance of baby from light source (30–35 cm).
Indications are based on hour-specific TSB thresholds from the AAP 2022 nomogram, which vary by gestational age (35–37+6 wk, 38–41+6 wk, ≥42 wk) and presence of neurotoxicity risk factors. Approximate thresholds for a term infant (≥38 wk) with no risk factors:
| Age (hours) | Start Phototherapy if TSB ≥ |
|---|---|
| 24 hours | ~12 mg/dL |
| 48 hours | ~15 mg/dL |
| 72 hours | ~17.5 mg/dL |
| 96+ hours | ~18–20 mg/dL |
Risk factors that lower the threshold: Gestational age <38 wk, isoimmune hemolytic disease, G6PD deficiency, asphyxia, sepsis, albumin <3 g/dL.
💡 Intensive Phototherapy
Use intensive phototherapy (irradiance ≥30 μW/cm²/nm, maximum surface area exposure, fibreoptic blanket below + LED above) when TSB is within 2–3 mg/dL of exchange transfusion threshold or rising rapidly despite standard phototherapy.
- Increased insensible water loss → dehydration (increase fluids by 10–20 ml/kg/day during phototherapy)
- Bronze baby syndrome — grayish-brown discoloration of skin, serum and urine in babies with cholestatic jaundice receiving phototherapy (due to accumulation of porphyrin photoproducts). Not harmful per se but indicates direct bilirubin elevation.
- Loose green stools — from bilirubin photoproducts in gut
- Hyperthermia or hypothermia
- Retinal damage (eyes must be covered at all times)
- Disruption of mother-infant bonding
- Rash / erythema
- Hypocalcemia (rare, in prolonged PT)
ET is indicated when TSB reaches the exchange transfusion threshold (per AAP 2022 nomogram, approximately 5 mg/dL above phototherapy threshold for that hour and gestational age). Also indicated in:
- Any TSB ≥25 mg/dL in term infant — regardless of age (or lower in preterm)
- TSB not responding to intensive phototherapy — rising >1–2 mg/dL/hour
- Signs of acute bilirubin encephalopathy (ABE) at any TSB level — emergency ET
- Cord bilirubin >4 mg/dL or cord Hb <10 g/dL in Rh disease (early ET)
- Severe anemia (Hb <10–11 g/dL) with ongoing hemolysis even if bilirubin below threshold
- Volume: 2 × blood volume = 2 × 80 ml/kg = 160 ml/kg
- Blood used: Freshest available packed RBCs reconstituted with Fresh Frozen Plasma (FFP) to a Hct of ~45–50% (or whole blood, cross-matched against mother's serum)
- For Rh disease: Rh-negative, ABO-compatible blood; for ABO incompatibility: Group O Rh-compatible packed cells + AB plasma
- Route: Umbilical venous catheter (UVC) — push-pull technique: aliquots of 5–20 ml drawn and replaced
- Removes: ~85–90% of antibody-coated RBCs and free maternal antibodies; reduces TSB by ~50% immediately (then rebounds)
- After ET: Rebound TSB rise is expected; resume phototherapy immediately
| Category | Complications |
|---|---|
| Vascular | UVC thrombosis, air embolism, vasospasm, portal hypertension (late) |
| Cardiac | Arrhythmias, bradycardia (citrate toxicity), cardiac arrest |
| Metabolic | Hypocalcemia (citrate binds Ca), hypoglycemia, hyperkalemia, acidosis |
| Hematological | Thrombocytopenia, coagulopathy, graft vs host disease (use irradiated blood) |
| Infectious | Sepsis (bacteremia), transfusion-transmitted infections |
| GI | Necrotizing enterocolitis (NEC) — especially in preterm; restrict feeds during ET |
Mortality of ET: ~1–3 per 1000 procedures in experienced hands.
IVIG (Intravenous Immunoglobulin) is used in isoimmune hemolytic jaundice (Rh or ABO incompatibility with positive DCT) when TSB is rising rapidly toward ET threshold despite intensive phototherapy.
Mechanism: Blocks Fc receptors on macrophages in RES → reduces phagocytosis of antibody-coated RBCs → decreases rate of hemolysis.
Dose: 0.5–1 g/kg IV over 2–4 hours; may repeat once after 12 hours if needed.
Evidence: Reduces the need for exchange transfusion by ~50% in Rh and ABO disease. Recommended by AAP 2004 (and carried forward in 2022 guidelines).
- Breastfeeding should be continued in most cases of neonatal jaundice — stopping breastfeeding is NOT routinely recommended
- Breastfeeding jaundice: Improve latch, increase feeding frequency to 8–12 times/24 hours; lactation support; supplementation with expressed breast milk or formula if weight loss >10% or inadequate intake
- Breast milk jaundice: Continue breastfeeding in most cases. Temporary interruption (24–48 hours) and replacement with formula may be considered only if bilirubin is dangerously elevated (near exchange transfusion threshold) and failing phototherapy
- If breastfeeding is interrupted, mother must express milk to maintain supply and resume promptly
Antenatal management:
- Rh antibody titer (indirect Coombs) in all Rh-negative mothers at booking and at 28 weeks
- If titer >1:16 → MCA Doppler (middle cerebral artery peak systolic velocity) for fetal anemia assessment
- Intrauterine transfusion (IUT) if fetal anemia confirmed before 34 weeks
Postnatal management: Exchange transfusion, IVIG, intensive phototherapy as needed.
Prevention with Anti-D (RhoGAM):
- Administer to Rh-negative mothers within 72 hours of delivery of an Rh-positive baby
- Dose: 300 µg IM (standard dose, covers 30 mL fetal blood)
- Also given at 28 weeks antenatal, after miscarriage, amniocentesis, antepartum hemorrhage
- Mechanism: Anti-D IgG coats fetal Rh-positive RBCs that have crossed into maternal circulation → cleared before sensitization occurs
Surgical: Kasai portoenterostomy (Hepatic portoenterostomy)
- Fibrous biliary remnant at porta hepatis is excised; a Roux-en-Y loop of jejunum is anastomosed to the liver capsule to establish bile flow
- Best results when performed before 60 days of life — bile drainage achieved in ~80% if done before 60 days vs ~20% after 90 days
- Post-Kasai: prophylactic antibiotics (to prevent cholangitis), ursodeoxycholic acid, fat-soluble vitamins (A, D, E, K)
- Even with successful Kasai, ~70–80% ultimately progress to cirrhosis and require liver transplantation by 20 years of age
Phototherapy can be discontinued when TSB falls to 2–3 mg/dL below the phototherapy threshold for that infant's age and gestational age, and the clinical condition is stable.
Rebound bilirubin: TSB should be rechecked 12–24 hours after stopping phototherapy (especially in infants with hemolysis or if discharged early) to ensure it is not rising significantly. Rebound of >1–2 mg/dL above the threshold requires resumption of phototherapy.
🔭 Recent Advances — Exam Q&A
The AAP 2022 Clinical Practice Guideline (Pediatrics 2022) updated the 2004 guidelines significantly:
- Extended applicability — now covers 35–42 weeks gestational age (vs previously ≥35 wk)
- New gestational age-specific nomograms — separate thresholds for 35–37+6 wk, 38–41+6 wk, ≥42 wk (not a single chart)
- Predischarge universal bilirubin screening strongly recommended — TcB or TSB before every newborn discharge
- Albumin incorporated — if albumin <3 g/dL → use lower phototherapy threshold (subtract 1 mg/dL from threshold)
- Standardized phototherapy irradiance threshold ≥8 μW/cm²/nm (start phototherapy threshold) and ≥30 μW/cm²/nm (intensive PT threshold)
- Follow-up timing post-discharge is now risk-stratified by Bhutani nomogram zone + gestational age
- Home phototherapy with appropriate monitoring recognized as option for select low-risk infants
LED (Light-Emitting Diode) phototherapy units emit narrow-spectrum blue-green light (peak ~460–490 nm) with high efficiency.
Advantages over conventional fluorescent lights:
- Higher irradiance achievable (≥30 µW/cm²/nm easily) → more effective
- Negligible heat generation → safer, less hypothermia/hyperthermia risk, baby can be kept closer
- Longer lifespan — no bulb degradation, consistent output
- Energy-efficient (lower power consumption)
- No UV or infrared emission
- Lighter and more portable — suitable for resource-limited settings
Tin-Mesoporphyrin (SnMP) is a heme oxygenase inhibitor. It competitively inhibits heme oxygenase, the rate-limiting enzyme in bilirubin production, thereby reducing bilirubin production at its source.
- A single IM dose can significantly reduce the need for phototherapy in high-risk neonates (G6PD deficiency, Rh disease)
- Has been studied in clinical trials and shown efficacy
- Limitation: transient photosensitivity (skin exposed to sunlight may develop erythema); not yet FDA approved for routine clinical use
- Remains an investigational agent — potential use in resource-limited settings and Crigler-Najjar Type I
- UGT1A1 gene variants (e.g., UGT1A1*28 — Gilbert's syndrome allele) are associated with reduced conjugating ability → severe neonatal jaundice, especially in combination with G6PD deficiency or hemolysis
- G6PD mutation testing — routine enzyme assay may be falsely normal in acute hemolysis (because older enzyme-deficient cells have been destroyed); molecular testing is definitive
- Genome-wide association studies have identified variants in SLCO1B1 (bilirubin transporter) associated with prolonged neonatal jaundice
- Future direction: genomic risk scoring at birth combined with TSB/TcB screening to personalize follow-up and prophylactic phototherapy decisions
Home phototherapy (using a fibreoptic bili-blanket or portable LED device) is an emerging option to reduce hospital readmission for jaundice.
Eligibility criteria (AAP 2022 recognized):
- Gestational age ≥38 weeks, otherwise healthy
- TSB below escalation threshold (not approaching ET level)
- No signs of ABE
- Reliable parents, adequate follow-up guaranteed
- No significant hemolysis
Advantage: Maintains breastfeeding, reduces maternal-infant separation, reduces cost.
Limitation: Irradiance of home devices may be lower; requires reliable TSB monitoring during treatment.
Liver transplantation is the definitive treatment for biliary atresia (BA) when Kasai fails or disease progresses to end-stage liver disease (cirrhosis). Key facts:
- BA is the most common indication for pediatric liver transplantation worldwide (~40–50% of pediatric LT cases)
- 5-year post-transplant survival: >85–90% in experienced centers
- Living donor liver transplantation (LDLT) — using left lateral segment from a parent; preferred when cadaveric organs are unavailable
- Timing: Kasai is attempted first (best before 60 days); transplant reserved for Kasai failure or end-stage liver disease
- Post-transplant: lifelong immunosuppression; excellent quality of life achievable
⚡ Key Points — Quick Revision
One-Liners for Exam
- Physiological jaundice: Onset day 2–3, resolves by day 14 (term)/day 21 (preterm), TSB <12 mg/dL, direct <2 mg/dL
- Pathological jaundice: Onset <24 h, TSB >17 mg/dL, rate >5 mg/dL/day, or prolonged (>14/21 days)
- Jaundice <24 hours = ALWAYS pathological — most common cause: ABO incompatibility; most severe: Rh incompatibility
- Kramer zones: Zone 1 (face) = 4–8; Zone 3 (umbilicus) = 8–16; Zone 5 (palms/soles) = >15 mg/dL
- Most common cause of jaundice in a term, thriving, breastfed baby >1 week: Breast milk jaundice
- Pale stools + prolonged jaundice = Biliary atresia — refer before 60 days for Kasai
- Bronze baby syndrome: Phototherapy in cholestatic (conjugated) jaundice → bronze discoloration
- Kernicterus tetrad: Choreoathetosis, upward gaze palsy, SNHL, dental dysplasia
- ABE early signs: Lethargy, hypotonia, poor suck, high-pitched cry
- Phototherapy works by: Configurational isomerization → structural isomerization (lumirubin) → photooxidation
- Optimal phototherapy wavelength: 460–490 nm (blue-green spectrum)
- Exchange transfusion volume: 2× blood volume = 160 mL/kg (DVET)
- ET removes: ~85% of antibody-coated RBCs; reduces TSB by ~50%
- IVIG dose: 0.5–1 g/kg — used in isoimmune hemolysis to reduce need for ET
- Anti-D (RhoGAM): 300 µg within 72 h of delivery to Rh-negative mother with Rh-positive baby
- DCT positive: Isoimmune hemolysis (Rh/ABO); negative hemolysis → consider G6PD, HS
- TcB unreliable: During and after phototherapy; always confirm with TSB near treatment threshold
- Hypothyroidism: Must always be excluded in prolonged jaundice (neonatal screening/TFT)
- Gold standard for jaundice assessment: Total serum bilirubin (fractionated)
- Gold standard for biliary atresia diagnosis: Intraoperative cholangiogram
- Most common indication for pediatric liver transplant: Biliary atresia
- AAP 2022: Extended to 35–42 wk; gestational age-specific nomograms; albumin incorporated in thresholds; universal predischarge TcB/TSB screening